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Gene Ontology (GO) terms are often used to interpret the results of microarray experiments. The most common approach is to per-
form Fisher’s exact tests to ﬁnd gene sets annotated by GO terms which are over-represented among the genes declared to be diﬀeren-
tially expressed in the analysis of microarray data. Another way is to apply Gene Set Enrichment Analysis (GSEA) that uses predeﬁned
gene sets and ranks of genes to identify signiﬁcant biological changes in microarray data sets. However, after correcting for multiple
hypotheses testing, few (or no) GO terms may meet the threshold for statistical signiﬁcance, because the relevant biological diﬀerences
are small relative to the noise inherent to the microarray technology. In addition to the individual GO terms, we propose testing of gene
sets constructed as intersections of GO terms, Kyoto Encyclopedia of Genes and Genomes Orthology (KO) terms, and gene sets con-
structed by using gene–gene interaction data obtained from the ENTREZ database. Our method ﬁnds gene sets that are signiﬁcantly
over-represented among diﬀerentially expressed genes which cannot be found by the standard enrichment testing methods applied on
individual GO and KO terms, thus improving the enrichment analysis of microarray data.
 2007 Elsevier Inc. All rights reserved.
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High-throughput technologies such as DNA micro-
arrays and proteomics are revolutionizing biology and
medicine. Global gene expression proﬁling, using micro-
arrays, monitors changes in the expression of thousands
of genes simultaneously. The outcome of such studies is
usually a list of genes whose expression varies between dif-
ferent conditions and therefore may be of interest for fur-
ther analysis. Lately, databases of other information
about genes are used in order to provide additional infer-
ence. Two of the most used are Gene Ontology (GO) [1],
and Kyoto Encyclopedia of Genes and Genomes (KEGG)
[2].1532-0464/$ - see front matter  2007 Elsevier Inc. All rights reserved.
doi:10.1016/j.jbi.2007.12.001
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E-mail addresses: igor.trajkovski@ijs.si (I. Trajkovski), nada.lavrac@
ijs.si (N. Lavracˇ), tolar003@umn.edu (J. Tolar).Gene Ontology (GO) is a controlled vocabulary of stan-
dardized biological terms used to annotate gene products.
It comprises several thousand terms, divided in three
branches: Molecular Function, Biological Process and Cel-
lular Component. KEGG Orthology (KO) is a collection
of manually drawn pathway maps representing the knowl-
edge on the molecular interaction and reaction networks
for Metabolism, Genetic Information Processing, Environ-
mental Information Processing, Cellular Processes and
Human Diseases.
Tests for gene set enrichment compare lists of diﬀeren-
tially expressed (DE) genes and non-DE genes to ﬁnd
which gene sets annotated by GO and KO terms are over-
or under-represented amongst the DE genes. Several
research groups have developed software to carry out Fish-
er’s exact tests to ﬁnd which gene sets are over-represented
among the genes found to be diﬀerentially expressed, e.g.,
[4,5] and other works cited in [6]. The Fisher’s test for
term T essentially compares the proportion of DE genes
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annotated by term T. Since there is a test for each of several
thousands of GO nodes, and hundreds of KO nodes, multi-
ple hypothesis testing must be taken into account. This is
usually done by the Bonferroni correction or a more
sophisticated correction controlling the False Discovery
Rate (FDR). Benjamini and Hochberg’s method [7] gives
valid control of the FDR even when the diﬀerent tests
are dependent.
Approaches based on Fisher’s exact testing have some
major limitations:
• After correcting for multiple hypothesis testing, in
selecting DE genes, no individual gene may meet the
threshold for statistical signiﬁcance, because the relevant
biological diﬀerences are small relative to the inherent
microarray technology noise.
• The opposite situation, one may be left with a long list
of statistically signiﬁcant genes without any common
biological function, so none of the gene sets annotated
by GO and KO terms is signiﬁcantly enriched.
• Single gene analysis may miss important eﬀects on path-
ways. Biological pathways often aﬀect sets of genes act-
ing jointly. An increase of 20% in the expression of all
gene members of a biological pathway can alter the exe-
cution of that pathway, and its impact on other pro-
cesses, signiﬁcantly more than a 10-fold increase in a
single gene [8].
• It is not rare that diﬀerent research groups studying the
same biological system report lists of DE genes they
found to be statistically signiﬁcant which have just a
small overlap [11].
• Since all genes annotated by a given GO term are also
annotated by all of its parents, closely related nodes
may be found separately signiﬁcant [15].
• Speciﬁc GO terms have few genes annotated, so there is
often not enough statistical evidence to ﬁnd these terms
as statistically signiﬁcant. The more general the GO
term, the more genes are annotated by it, but the less
useful the term is as an indication of the function of
the diﬀerentially expressed genes [12].
The described problems have recently triggered the
development of numerous methods described below.
1.1. Related work
Several methods have been developed recently to over-
come the analytical challenges presented in the previous
section. For improving the sensitivity of enrichment detec-
tion, Gene Set Enrichment Analysis (GSEA) [9] and Para-
metric Analysis of Gene Set Enrichment (PAGE) [13] were
developed. GSEA calculates an enrichment score (ES) for a
given gene set using ranks of genes and infers the statistical
signiﬁcance of ES against the ES-background distribution
calculated by permutating the labels of the original data
set. In the new version of GSEA, GSEA-P [10], there isan option for importing gene sets from MSigDB (Molecu-
lar Signatures Database) and testing them for enrichment,
by that increasing the probability for ﬁnding enriched gene
sets.
In contrast, PAGE calculates a Z-score for a given gene
set from a parameter such as t-score value calculated on the
basis of two experimental groups and infers statistical sig-
niﬁcance of the Z-score against the standard normal distri-
bution. These two methods are capable to ﬁnd enriched
gene sets, not detectable by the standard Fisher’s exact test.
Grossmann et al. [14] take into account the hierarchical
structure of the GO by measuring the over-representation
of each term relative to its parent terms. Alexa et al. [15]
downweight the contribution of genes to the calculation
of over-representation of a term if the children of that term
have already been found signiﬁcantly enriched. These two
methods do not improve the statistical power, as the num-
ber of genes in each hypothesis test will be smaller than in
the usual term-by-term tests, as double counting is penal-
ized. However, they do help to improve the interpretation,
since they produce just one (or at least not too many) sig-
niﬁcant p-values for each signiﬁcant region of the graph.
Levin et al. [12] use grouping of similar GO terms (which
are close in the GO graph) in order to increase the statisti-
cal power. The reason is that the lower terms in the GO
have few genes annotated by it, and can not be found sta-
tistically signiﬁcantly enriched. Therefore, the authors of
[12] group several terms to increase the size of the gene sets
tested for enrichment. This approach is useful and can ﬁnd
enriched gene sets not detectable by standard screening of
GO terms, but it is diﬀerent form ours: we construct new
gene sets as intersection of gene sets deﬁned by Molecular
Function, Biological Processes and Cellular Component
terms of GO and KO terms, whereas [12] create new gene
sets by making union of similar terms in GO. Concerning
the usage of KO term in enrichment analysis, the work of
Mao et al. [3] uses KO terms for automated annotation
of large sets of genes, including whole genomes, and auto-
mated identiﬁcation of pathways. This is done by identify-
ing both the most frequent and the statistically signiﬁcantly
enriched pathways.
1.2. The proposed SEGS approach
In this work, we propose a novel approach for searching
of enriched gene sets (SEGS) which proves to further
improve the gene set enrichment results and by that the
interpretation of gene expression data. Our approach is
based on the eﬃcient generation of new biologically rele-
vant gene sets, that are tested for possible enrichment.
The new gene sets are generated as intersections of GO
and KO terms and gene sets deﬁned with the help of
gene–gene interaction data. Testing the enrichment of these
gene sets with the standard methods (Fisher’s exact test,
GSEA and PAGE) shows that our method ﬁnds gene sets
constructed from GO and KO terms signiﬁcantly over-rep-
resented amongst diﬀerentially expressed genes, while these
4 This number of terms was available in KO in September 2007.
5 ftp://ftp.ncbi.nlm.nih.gov/gene/
6 http://www.bind.ca
7
590 I. Trajkovski et al. / Journal of Biomedical Informatics 41 (2008) 588–601GO and KO terms are not found to be enriched by Fisher’s
test, GSEA or PAGE, thus improving the enrichment anal-
ysis of microarray data.
The paper is organized as follows. Section 2 gives some
background information about the publicly available
resources of biological knowledge, followed by the meth-
ods for ﬁnding DE genes and methods for testing the gene
set enrichment: Fisher’s exact test, GSEA and PAGE. Sec-
tion 3 presents the main idea of our SEGS approach, and
the methodological steps taken in the construction of the
new gene sets. Section 4 presents the results of the experi-
ments and in Section 5 we draw the main conclusions
and plans for further work.
2. Background
In this section, we ﬁrst provide background information
about the resources of biological knowledge, distributed
across several publicly available databases. Then we pres-
ent the most popular methods for ﬁnding the diﬀerentially
expressed genes and calculating the gene set enrichment.
2.1. Resources of biological knowledge
2.1.1. Gene Ontology
Gene Ontology (GO)1 is a database of standardized bio-
logical terms used to annotate gene products. In total it
comprises about 23,000 terms,2 divided in three branches:
Molecular Function, Biological Process and Cellular Com-
ponent. Each branch can be represented as a directed acy-
clic graph (DAG) relating terms (or nodes) of diﬀerent
degrees of speciﬁcity, with directed links from less speciﬁc
to more speciﬁc terms. Each node in the graph can have
several parents (broader related terms) and children (more
speciﬁc related terms). See Fig. 1 presenting a small section
of the GO graph. Annotation of a gene by any node A
implies its automatic annotation by all ancestors of A
(the set of broader terms related to A by directed paths).
Genes can be annotated by several terms, however note
that many genes have not been annotated at all.
2.1.2. Kyoto Encyclopedia of Genes and Genomes Ortology
Kyoto Encyclopedia of Genes and Genomes (KEGG)
includes KEGG orthology (KO)s3 that is a database of
manually drawn pathway maps representing the knowledge
on the molecular interaction and reaction networks. A met-
abolic pathway is a series of chemical reactions occurring
within a cell, catalyzed by enzymes (genes), resulting in
either the formation of a metabolic product to be used or
stored by the cell, or the initiation of another metabolic
pathway. That for each KEGG pathway (KO term) deﬁnes
a set of genes that can be considered for statistical enrich-
ment testing and by that detecting disrupted pathways. The1 http://www.geneontology.org
2 This number of terms was available in September 2007.
3 http://www.genome.jp/kegg/pathway.htmlKO is structured as a DAG hierarchy of four ﬂat levels.
The top level consists of the following ﬁve categories:
Metabolism, Genetic Information Processing, Environ-
mental Information Processing, Cellular Processes and
Human Diseases. The second level divides the ﬁve func-
tional categories into ﬁner sub-categories. The third level
corresponds directly to the KEGG pathways, and consists
of 272 terms.4 See Fig. 2 for an example of a small section
of the KO hierarchy. Note that some of the KO terms
appear also as process terms in the GO.2.1.3. ENTREZ
ENTREZ5 is a database that provides various informa-
tion about genes and their products, including gene
annotations with GO and KO terms (see Fig. 3) and
gene-gene interaction data. As the collection of interaction
data in a consistent, well-annotated format is essential for
discovering of gene functions and benchmarking of high
throughput interaction studies, a number of gene–gene
interaction databases were developed. The examples of
such a databases are BIND,6 BioGRID,7 EcoCyc8 and
HPRD.9 ENTREZ (among other functionality) is a repos-
itory of these interaction databases, to house and distribute
comprehensive collections of gene–gene interactions. The
number of all gene-gene interactions in ENTEZ is about
118,000.102.2. Methods for ﬁnding diﬀerentially expressed genes
Selection of DE genes is the ﬁrst step performed in the
functional interpretation of microarray data. DE genes
are the genes that are expressed diﬀerently (relative to the
reference) between the given classes of microarray data.
The most frequently used algorithms for the selection of
DE genes are presented below. Mathematical deﬁnitions
used by these methods are given in Fig. 4.2.2.1. Fold change method
The simplest, non-statistical test method used for the
selection of DE genes is the fold change method. In this
method, the ratios between expression levels in two condi-
tions are evaluated. All genes with a ratio of expression
level higher than an arbitrary cut-oﬀ value are considered
to be diﬀerentially expressed. The fold change method in
its original form can be strongly biased by an inappropriate
normalization. This problem has been addressed by the
development of intensity-speciﬁc thresholds [16]. However,
as this simple method is not a statistical test, it has no asso-http://www.thebiogrid.org
8 http://www.ecocyc.org
9 http://www.hprd.org
10 This number of interactions was available in ENTEZ in September
2007.
Fig. 1. A part of GO providing the annotations concerning positive regulation of muscle cell diﬀerentiation.
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tion of genes as being diﬀerentially expressed.2.2.2. Signal to noise ratio test
The signal to noise ratio (SNR) test identiﬁes genes with
large diﬀerence in the mean level of expression between two
groups and at the same time have small variation of expres-
sion within each group. This test does not assume the
equality of standard deviations (variances). The SNR com-
bined with diﬀerent feature selection methods has been the
method of choice in most classiﬁcation studies performed
at the Whitehead Institute, MIT [20–22], as well as by sev-
eral other groups.
2.2.3. Student’s t test
The Student’s t test is one of the simplest statistics-based
methods used in microarray analysis, both for estimating
the accuracy of results from replicated experiments and
for the selection of DE genes. The t test for independent
samples (Student’s t test) allows for the determination of
an expression pattern that has a maximal diﬀerence in the
mean levels of expression between two groups of indepen-
dent samples with a minimal variation of expression within
each group. Therefore, the t test has been used frequently
for the selection of DE genes in microarray experiments[17–19]. The diﬀerence in gene expression between sample
types is expressed as the p value which evaluates the prob-
ability that random sampling would result in the observed
diﬀerence. As the Student’s t test determines the signiﬁ-
cance of the diﬀerence between the means of two indepen-
dent samples, it is a good choice when: (i) the two samples
are independently and randomly drawn from the source
population(s); (ii) the measurements for both samples have
an equal interval; and (iii) the source population(s) can be
reasonably assumed to have a normal distribution.2.3. Methods for evaluating gene set enrichment
Here, we present three methods for evaluating gene set
enrichment. The ﬁrst one, Fisher’s exact test, is a threshold
based procedure. It accept two lists of genes: diﬀerentially
expressed and all other genes. The next two are from the
family of threshold-free procedures. They accept only one
list of genes, ranked by some criterion (e.g., the t score
value of the genes).2.3.1. Fisher’s exact test
When using Fisher’s exact test, the score for a gene set
annotated by GO term S is the degree of independence
between the two properties:
Fig. 2. A part of KO providing the annotations concerning metabolism.
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B ¼ gene is annotated by GO term S
Testing the independence of these two properties corre-
sponds to the Fisher’s exact test [6], and is computed by the
following procedure:
(1) Let N be the number of genes on a microarray.
(2) S is a GO term.
(a) M genes 2 S.
(b) N M genes 62 S.
(3) Let k be the number of DE genes.
(4) The probability of having exactly x, out of k DE
genes, annotated by S is computed as follows:
P ðX ¼ x j N ;M ; kÞ ¼
M
x
 
N M
k  x
 
N
k
 
(5) The Fisher’s score determines the probability of hav-
ing at least x genes, out of k DE genes, annotated by
S:p ¼ 1
Xx1
i¼0
M
i
 !
N M
k  i
 !
N
k
 !2.3.2. Gene Set Enrichment Analysis (GSEA)
GSEA [9] considers experiments with gene expression
proﬁles from samples belonging to two classes. First, genes
are ranked based on their t-score values. Given a prede-
ﬁned set of genes S (e.g., genes involved in some biological
process) the goal of GSEA is to determine whether the
members of S are randomly distributed throughout the
ranked gene list (L) or primarily found at the top of the list.
There are two major steps of the GSEA method:
(1) Calculation of the enrichment score. The enrichment
score (ES) reﬂects the degree to which a set S is over-
represented at the top of the ranked list L. The score
is calculated by walking down the list L, increasing a
running-sum statistic when encountering a gene in S
and decreasing it when a gene is not in S. The magni-
tude of the increment depends on the size of S,
j S j¼ M , and the total number of genes N. The
Fig. 5. The ‘spectral line’s show the positions of genes members of a gene
set S on the ranked gene list. This ﬁgure is borrowed from the
supplementary material of [9].
Fig. 3. A part of data providing the annotation of gene LDHA lactate dehydrogenase with KO and GO terms, contained in the ENTREZ database.
Fig. 4. Mathematical deﬁnitions of the selected statistical methods used
for the selection of DE genes. I and U are two sets of microarray data that
deﬁne two separate classes, I and U, respectively. X ij is the expression of
gene i in sample j, lCðiÞ is the mean of the expression of gene i in class C,
rCðiÞ is the standard deviation of the expression of gene i in class C.
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encountered in a random walk (see Fig. 5). If
L ¼ ½g1; g2; . . . ; gN  is a ranked list of genes, according
to their t-score, enrichment score ES is calculated as:
ESðSÞ ¼ max
16i6N
j HitðS; iÞ MissðS; iÞ j ð1Þ
where
HitðS; iÞ ¼
X
gj2S
16j6i
1
M
; MissðS; iÞ ¼
X
gj2S
16j6i
1
N M
(2) Estimation of the signiﬁcance level of ES. The statis-
tical signiﬁcance of the ES is computed by using an
empirical phenotype-based permutation test proce-
dure that preserves the complex correlation structureof the gene expression data. Speciﬁcally, one per-
mutes the phenotype labels and recomputes the ES
of the gene set for the permuted data, which generates
a null distribution for the ES. The empirical, p-value
of the observed ES is then calculated relative to this
null distribution.2.3.3. Parametric Analysis of Gene set Enrichment (PAGE)
According to the Central Limit Theorem in statistics
[23], the distribution of the average of randomly sampled
n observations tends to follow the normal distribution as
the sampling size n becomes larger, even when the parent
distribution from which the average is calculated is not
594 I. Trajkovski et al. / Journal of Biomedical Informatics 41 (2008) 588–601normal. In other words, when the mean and variance of the
parent distribution (whether it is normally distributed or
not) are l and r2, the average of n observations from the
parent distribution will follow a normal distribution of
mean l and variance r
2
n when the sampling size n is large
enough.
In PAGE [13], the parent distribution is a distribution of
any numerical values (also termed parameters here) that
describe diﬀerential expression of genes among samples in
a microarray data set. In most cases, the distribution of a
parameter, i.e., t-score values of the genes, is not normally
distributed. However, as the Central Limit Theorem states,
when we sample n observations from the parent distribu-
tion of a parameter, the average of the sampled observa-
tions tends to follow the normal distribution as our
sampling size n becomes larger. Here, we deﬁne sampled
observations as parameter values for the genes within pre-
deﬁned gene sets, groups of genes having similar functions,
genes in the same biological pathway, and so on. If we
deﬁne a gene set of suﬃciently large size, i.e., 30, we can
use the normal distribution to test the statistical signiﬁ-
cance of that gene set.
The following procedure is used for p value calculation
of a gene set S:
(1) From input data containing t-score values for each
gene, mean of all t-score values ðlÞ and standard
deviation of all t-score values ðrÞ are calculated (this
is a common step for the calculation of p values of all
genes).
(2) The mean of t-scores ðlSÞ of gene members of S is
calculated.
(3) If M is the size of S then the Z-score is calculated as
Z ¼ ðlS  lÞ 
ﬃﬃﬃﬃﬃ
M
p
r
ð2Þ
Gene set p value is computed from the Z-score, using
numerical methods.
3. SEGS: Construction of new gene sets
Methods that test for enrichment of GO terms11 have
been proposed by [4,5,24,25]. A comparative study of com-
monly used tools for analyzing GO term enrichment was
presented by [6]. Papers [14,15] present two novel algo-
rithms that improve GO term scoring using the underlying
GO graph topology. None of the papers includes the gene-
gene interaction data, and none of them presents a method
for the construction of novel gene sets; they only calculate
the enrichment of an a-priory given list of gene sets.
We propose a method that additionally to the testing of
the enrichment of individual GO and KO terms, tests the11 In the rest of the paper, GO or KO term enrichment is used, meaning
the enrichment (i.e. diﬀerential expression) of a set of genes, annotated by
the given GO or KO term.enrichment of newly deﬁned gene sets constructed by the
combination of GO terms, KO terms and gene sets deﬁned
by taking into account the gene–gene interaction data from
ENTREZ.
3.1. Properties of GO and KO terms
First, let us state some properties of gene annotations by
GO and KO terms:
• one gene can be annotated by several terms,
• if a gene is annotated by a term T then it is annotated by
all the ancestors of T, and
• a term may have thousands of genes annotated by it.
From this we can conclude that:
• each GO and KO term deﬁnes a gene set,
• one gene can be a member of several gene sets, and
• some gene sets are subsets of other gene sets.
Second, let Func (or Proc, Comp, respectively) denote
the set of gene sets that are deﬁned by the GO terms that
are subterms of the term Molecular Function (or Biological
Process, Cellular Component, respectively), and let Path
denote the set of gene sets deﬁned by the KO terms.
3.2. Basic operations for gene set construction using GO, KO
and ENTREZ
Our method relies on two ideas for the construction of
new gene sets: inclusion of gene–gene interactions, and
construction by the intersection of gene sets.
3.2.1. Gene–gene interactions
There are cases when some abrupted processes are not
detectable by the enrichment score. One of the reasons
can be that gene members of that process have a slight
increase/decrease in their expression, but this increase/
decrease can have a much larger eﬀect on the genes that
interact with them. Therefore, we propose to construct a
gene set whose members interact with members of another
gene set (see Fig. 6). The gene–gene interaction data can beFig. 6. Construction of a new gene set, int (S), from existing gene set S.
All gi 2 int (S) are interacting with some gj 2 S. Gene sets S and int (S) do
not need to intersect.
Fig. 7. Construction of a new gene set, consisting of the members of the
‘‘leukocyte migration’’ process which interact with genes on the cell
surface.
Fig. 8. Data ﬂow of the proposed SEGS method for the generation of
enriched gene sets.
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formally described as follows:
if S 2 Func (or Proc;Comp; Path, respectively) then
intðSÞ ¼ fgj j gj interacts with gi 2 Sg is added to Func
(or Proc;Comp; Path).
3.2.2. Intersection of gene sets
There are cases where some gene sets are not signiﬁ-
cantly enriched, but their intersection is signiﬁcantly
enriched. For example, it can happen that a gene set
deﬁned by molecular function F is not enriched because a
lot of genes in diﬀerent parts of the cell execute it, and
one can not expect that all of them will be over/underex-
pressed, but if genes with that function in a speciﬁc part
of the cell ðCpartÞ are abnormally active, then this can be
elegantly described by deﬁning the following gene set:
S ¼ funcðF Þ
\
CompðCpartÞ ¼ SF
\
SCpart :
Gene set construction due to gene sets intersection is for-
mally described as follows:
if S1 2 Func, S2 2 Proc, S3 2 Comp and S4 2 Path,then
Snew ¼ S1
T
S2
T
S3
T
S4 is a newly deﬁned gene set.
An example of this type of construction is presented in
Fig. 7.
The newly deﬁned gene sets are interpreted very intui-
tively. For example, gene set S deﬁned as the intersection
of ‘‘functional’’ term A and ‘‘process’’ term B
S ¼ funcðAÞ; procðBÞ  SA
\
SB
is interpreted as: genes that are part of process B and have
function A.
The number of potentially newly deﬁned gene sets is
huge. It is currently12 estimated at:
j Func j  j Proc j  j Comp j  j Path j 47 1012
If for each of these sets we compute its enrichment score,
which in case of GSEA takes linear time in the number of
genes ð 2 104Þ, then we need  1018 numeric operations.
If we want to statistically validate discovered enriched gene
sets, usually with 1000 permutation tests, we get  102112 In September 2007, j Func j¼ 7513; j Proc j¼ 12; 549; j Comp j¼ 1846
and j Path j¼ 272.operations, that is well above the average performance of
today’s PCs. Therefore, we need to eﬃciently search the
gene set space for potentially enriched gene sets, as pro-
posed below.3.3. Pruning the search space for enriched gene sets
The ﬁrst idea for improvement is that we are not inter-
ested in generating all possible gene sets, but only those
that are potentially enriched. This can be achieved by gen-
erating gene sets that have some predeﬁned minimum num-
ber of genes at the top of the ranked list, i.e. according to
the genes t-scores, for example, 3 in the ﬁrst 100, or 10 in
the ﬁrst 300 genes of the list. That is a weak constraint con-
cerning the biological interpretation of the results, because
we are not really interested in gene sets that do not have
some minimum number of genes at the top of the list,
but it is a hard constraint concerning the pruning of the
search space of all gene sets. By having this constraint we
can use the GO and KO topology to eﬃciently generate
all gene sets that satisfy the constraint.
As the GO is a directed acyclic graph, with the root of
the graph being the most general term, this means that if
one term (gene set) does not satisfy our constraint, than
all its descendants will also not satisfy it, because they
cover a subset of the genes covered by the given term. In
this way we can signiﬁcantly prune the search space of
potentially enriched gene sets. Therefore, we ﬁrst construct
gene sets from the top nodes of the GO and KO, and if we
fail to satisfy the given constraint we do not reﬁne the last
added term.
The pseudo code, presented in Appendix A, implements
the basic idea for eﬃcient construction of potentially
enriched gene sets.
The proposed method has the data ﬂow model shown in
Fig. 8.4. Experiments
Note that this paper does not address the problem of dis-
criminating between the classes. Instead, for the given target
class we aim at ﬁnding relevant enriched gene sets that can
capture the underlying biology characteristic for the class.4.1. Brief description of datasets
We applied the proposed SEGS methodology to three
classiﬁcation problems: leukemia [20], diﬀuse large B-cell
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them are binary classiﬁcation problems. The leukemia data
includes 48 acute lymphoblastic leukemia (ALL) samples
and 25 acute myeloid leukemia (AML) samples, each with
7074 gene expression values. The DLBCL data set includes
7070 gene expression proﬁles for 77 patients, 58 with
DLBCL and 19 with follicular lymphoma (FL). The pros-
tate tumor data set includes 12,533 genes measured for 52
prostate tumor and 50 normal tissue samples. The data for
these three data sets were produced from Aﬀymetrix gene
chips and are available at http://www.genome.wi.mit.edu/
cancer/.
4.2. Experimental results
To illustrate the straightforward interpretability of the
enriched gene sets found by our approach, we provideTable 1
Five most enriched gene sets (according to the aggregate ranking) found in th
Gene set Set
size
Ge
Enriched in ALL En
func(‘DNA binding’), int(comp(‘nucleoplasm’)),
int(proc(‘histone modiﬁcation’))
41 int
int
int(func(‘transcrip. repressor activ.’)), comp(‘nucleus’),
int(proc(‘histone modiﬁcation’)), int(path(‘Long-term
potentiation’))
50 int
int
int(func(‘acetyltransferase activity’)), int(comp(‘nucleus’)),
int(proc(‘ubiquitin cycle’)), int(path(‘Signal Transduction’))
45 int
pro
int(func(‘nucleotidyltransferase activ.’)), comp(‘nucleus’),
int(proc(‘DNA repair’)), int(path(‘Cell cycle’))
84 int
pro
int(func(‘zinc ion binding’)), comp(‘intracellular organelle
part’), int(proc(‘protein complex assembly’)), int(path(‘Wnt
signaling pathway’))
64 int
me
ad
Table 2
Five most enriched gene sets (according to the aggregate ranking) found in th
Gene set Set
size
Ge
Enriched in DLBCL En
int(func(‘transf.phosph.cont.groups’)), int(comp(‘nuclear
part’)), proc(‘biopolymer metabolism’)
33 com
int(func(‘transf.phosph.cont.groups’)), comp(‘nucleus’),
proc(‘DNA metabolism’), int(path(‘Cell cycle’))
46 com
int(func(‘DNA binding’)), int(comp(‘nucleus’)), proc(‘DNA
replication’), int(path(‘Cancers’))
35 fun
int
int(func(‘DNA binding’)), int(comp(‘nucleus’)),
proc(‘biopolymer metabolism’), int(path(‘Pancreatic
cancer’))
50 fun
int
int(func(‘transcrip. factor act.’)), int(comp(‘nucleus’)),
proc(‘biopolymer metabolism’), int(path(‘Cell Growth and
Death’))
64 pro
Intthe most enriched gene sets for all classes in the three men-
tioned classiﬁcation problems (see Tables 1–3). Because we
use three statistical tests, which give three diﬀerent rank-
ings for the enrichment of the gene sets, we calculated the
aggregate rank for each gene set by summing its ranks from
the separate rankings.
Concerning the number of generated gene sets, for the
leukemia data set we generated 210,762 (ALL) and
127,187 (AML) gene sets, for DLBCL data set we gener-
ated 158,152 (DLBCL) and 78,048 (FL) gene sets, and
for the prostate data set we generated 28,027 (tumor) and
62,567 (normal) gene sets, that satisﬁed the constraint to
have at least three genes in the ﬁrst 100, or 10 in the ﬁrst
300 most diﬀerentially expressed genes. We also set an
additional constraint needed for the PAGE algorithm,
the size of the generated gene sets, which was chosen to
be larger than 30.e leukemia dataset by using GO, KO and ENTREZ
ne set Set
size
riched in AML
(comp(‘lysosome’)), int(proc(‘response to ext. stimulus’)),
(path(‘Immune System’))
37
(comp(‘membrane part’)), proc(‘inﬂammatory response’),
(path(‘Human Diseases’))
38
(func(‘peptidase activity’)), int(comp(‘integral to pl. membrane’)),
c(‘defense response’)
31
(func(‘metal ion binding’)), int(comp(‘integral to membrane’)),
c(‘inﬂammatory response’)
39
(func(‘endopept. inhibitor act.’)), int(comp(‘integral to pl.
mbrane’)), int(proc(‘response to pest.path.par.’)), int(path(‘Cell
hesion molecules’))
43
e DLBCL dataset by using GO, KO and ENTREZ
ne set Set
size
riched in FL
p(‘integral to membrane’), proc(‘humoral immune response’) 47
p(‘plasma membrane’), path(‘Hematopoietic cell lineage’) 40
c(‘transmembrane receptor act.’), int(comp(‘membrane’)),
(proc(‘immune response’)), int(path(‘Immune System’))
83
c(‘transmembrane receptor act.’), comp(‘integral to membrane’),
(proc(‘immune response’)), int(path(‘Env. Inf. Processing’))
100
c(‘humoral immune response’), int(path(‘Sign. Molec. &
er.’))
48
Table 3
Five most enriched gene sets (according to the aggregate ranking) found in the prostate dataset by using GO, KO and ENTREZ
Gene set Set
size
Gene set Set
size
Enriched in prostate cancer Enriched in normal
func(‘struct. constituent of ribosome’),comp(‘intracellular
organelle part’), proc(‘protein biosynthesis’),
path(‘Ribosome’)
52 int(func(‘receptor binding’)), comp(‘integral to membrane’) int(proc(‘+
regul. of cell prolif.’)), int(path(‘Human Diseases’))
143
func(‘RNA binding’), comp(‘ribosome’), proc(‘protein
biosynthesis’)
45 int(func(‘protein kinase act.’)),int(comp(‘integral to membrane’)),
int(proc(‘Ras protein sig. transd.’)), int(path(‘Fc eps. RI sig. path.’))
162
func(‘RNA binding’), comp(‘cytoplasmic part’),
path(‘Genetic Information Processing’)
51 int(func(‘protein kinase act.’)), int(comp(‘integral to membrane’)),
int(proc(‘Ras protein sig. transd.’)), int(path(‘Focal adhesion’))
172
func(‘struct. constituent of ribosome’), comp(‘cytost.
ribosome (s. Eukaryota)’), proc(‘protein biosynthesis’)
62 int(func(‘receptor binding’)), int(comp(‘cytosol’)), int(proc(‘+ regul. of
cell prolif.’)), int(path(‘Colorectal cancer’))
178
func(‘RNA binding’), comp(‘intracellular organelle part’) 120 int(func(‘protein kinase activity’)), int(comp(‘integral to membrane’)),
int(proc(‘Ras protein sig. transd.’)), int(path(‘Nat.kill.cell.medi.cyt.’))
170
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The following procedure was used to calculate the sig-
niﬁcance of the observed enrichment of a gene set by com-
paring it with the set of maximal enrichment scores
computed from the same datasets but with randomly
assigned phenotypes (class labels):
(1) Randomly assign the original phenotype (class) labels
to samples, reorder genes according to their t-score
values, and re-compute the enrichment scores.
(2) Repeat step 1 for 1000 permutations, and create a his-
togram of the corresponding best enrichment scores
for all three tests.
(3) Estimate the p-value for the calculated enrichment
score value of the gene set S using the histogram com-
puted at step 2. If there was not a case where random
labeling of the examples gives a better enrichment
score, then p-value <0.001.
We use class labeled permutation because it preserves
gene–gene correlations and, thus, provides a more biologi-
cally reasonable assessment of the signiﬁcance than the one
obtained by randomly permuting the genes.
After the calculation of the gene sets enrichment, we
remove gene sets that have too general descriptions. For
example, if gene set S1 is more enriched then gene set S2,
and S1 has a more speciﬁc description than S2, then S2 is
eliminated. Note that S1 ¼ T 11
T
T 12
T
T 13
T
T 14 is more
speciﬁc than S2 ¼ T 21
T
T 22
T
T 23
T
T 24 if T 1j is a subterm
of T 2j for j ¼ 1 . . . 4.
Table 4 provides the results of the empirical comparison
of SEGS with single GO and KO term analysis for the
ALL class of the leukemia dataset. Extensive results for
all three datasets are given in the supplementary material.13
We can see that on all tests the best constructed gene sets
are found to be more enriched than the most enriched gene13 http://kt.ijs.si/igor-trajkovski/SEGS/supplement.htmlsets deﬁned by taking into account only single GO and KO
terms.
Concerning the joint coverage of the ﬁve most enriched
gene sets, for the ALL class of the ﬁrst problem, we found
that their union consists of 179 genes. The sum of the car-
dinalities of these ﬁve sets is 284. This means that we did
not ﬁnd ﬁve diﬀerent descriptions of the same gene set,
but these descriptions cover quite diﬀerent sets of genes.
Similar results were obtained for all the classes of the other
two datasets.4.4. Biomedical signiﬁcance of the discovered enriched gene
sets
The goal of this study is to provide a better understand-
ing of the biology of malignancies through the use of the
background knowledge encoded in GO, KO and
ENTREZ. To do so, we have examined biological func-
tions of genes using the entire pathway changes which
are more likely (than the changes in the expression of indi-
vidual genes) to represent meaningful alterations of cellular
metabolism in cancers. In its overall design this study ﬁlls
in the gap of knowledge represented by the common reduc-
tionist approach to the interpretation of microarray data
whereby increased or decreased expression of a single gene,
rather than behavior of a functionally linked group of
genes (a pathway), is used as a readout. In this way, discov-
ered enriched gene sets (described in Tables 1–3) for ALL
vs. AML, DLBCL vs. follicular lymphoma, and prostate
cancer vs. normal tissue, expand our understanding of pre-
dictors of clinical behavior of these cancers. Expert inter-
pretation of several found enriched gene sets for each of
the three problems is given below.4.4.1. ALL vs. AML
Acute leukemias strike 3–4 people per 100,000 every
year. Two major classes of acute leukemias exist: acute
lymphoblastic leukemia (ALL) and acute myelogenous leu-
kemia (AML). The peak incidence of ALL is in childhood
Table 4
Comparison of the most enriched gene sets constructed using GO, KO and ENTREZ compared to the most enriched gene sets deﬁned by singe GO and
KO terms, for the ALL class in the leukemia data set
Gene set Set Fisher GSEA PAGE Aggregate
size p-value (adj p-value) ES score (adj p-value) Z-score(adj p-value) rank (ranks)
Enriched gene sets in ALL (the same as in Table 1)
func(‘DNA binding’),
int(comp(‘nucleoplasm’)),int(proc(‘histone
modiﬁcation’))
41 4:18 1018(0.001) 0.33(0.001) 8.92(0.001) 5ð2þ 2þ 1Þ
int(func(‘transcrip. repressor activ.’)),
comp(‘nucleus’), int(proc(‘histone
modiﬁcation’)), int(path(‘Long-term
potentiation’))
50 4:96 1019(0.001) 0.31(0.001) 7.37(0.001) 9ð1þ 3þ 5Þ
int(func(‘acetyltransferase activity’)),
int(comp(‘nucleus’)), int(proc(‘ubiquitin
cycle’)), int(path(‘Signal Transduction’))
45 1:38 1017(0.001) 0.21(0.005) 5.110.015) 16ð3þ 6þ 7Þ
int(func(‘nucleotidyltransf. activ.’)),
comp(‘nucleus’), int(proc(‘DNA repair’)),
int(path(‘Cell cycle’))
84 1:16 1015(0.004) 0.25 (0.002) 5.90(0.002) 17ð6þ 5þ 6Þ
int(func(‘zinc ion binding’)), comp(‘intracellular
organelle part’), int(proc(‘protein complex
assembly’)), int(path(‘Wnt signaling pathway’))
64 5:70 1016(0.002) 0.28(0.001) 5.05(0.021) 19ð5þ 4þ 10Þ
Enriched gene sets in ALL (using single GO and KO terms analysis)
proc(‘DNA metabolic process’) 314 9:14 107(0.031) 0.14(0.018) 4.47(0.003) 8ð3þ 4þ 1Þ
comp(‘nucleus’) 1461 3:51 109(0.012) 0.13(0.020) 3.29(0.045) 11ð1þ 5þ 5Þ
comp(‘chromosome’) 139 5:28 107(0.025) 0.19(0.004) 3.11(0.061) 15ð2þ 1þ 12Þ
path(‘pyrimidine metabolism’) 48 9:21 106(0.072) 0.15(0.010) 4.13(0.009) 16ð11þ 3þ 2Þ
func(‘DNA binding’) 810 1:15 106(0.048) 0.10(0.071) 3.89(0.011) 18ð7þ 8þ 3Þ
proc(‘nucleobase, nucleoside, nucleotide & nucleic
acid met. proc.’)
1321 4:31 106(0.050) 0.08(0.125) 3.65(0.022) 23ð9þ 10þ 4Þ
path(‘nucleotide metabolism’) 101 1:02 106(0.040) 0.07(0.144) 3.19(0.053) 28ð5þ 13þ 10Þ
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cases) and it is rare in older adults. In contrast, the median
age of AML patients is 60 years and its incidence increases
gradually with age. Therefore, as ALL and AML are dis-
tinct in clinical presentation, we expected that there would
be correlative diﬀerences in their biology, as evidenced by
microarray expression data.
In fact, the results of our analysis show that functionally
linked groups of genes involved in DNA binding (a process
whereby transcription factors exert their positive or nega-
tive eﬀects on the ﬁrst phase of protein expression, i.e.,
transcription of DNA sequence into RNA) and in histone
modiﬁcation (a process whereby transcription machinery is
either allowed or prohibited from the access to DNA in the
ﬁrst place) are prominent in ALL cellular pathways, with
41 genes and 50 genes in the ﬁrst and second ALL gene
sets, respectively [31,32].
This is in agreement with the current understanding of
the role of transcriptional activators and repressors in
ALL, as is the role of ubiquitin (the third ALL gene set
with 45 genes) and DNA repair in this condition (the
fourth ALL gene set with 84 genes). Ubiquitin cascade is
the major cellular mechanism for recycling proteins, thus
regulating their activity and permanence (half-life) in thecell. DNA repair is a key regulator of survival of the cell,
normal or malignant, as the unrepaired DNA typically pre-
cludes cellular division and proliferation. Lastly, the ﬁfth
ALL gene set (64 genes) identiﬁes the evolutionarily con-
served Wnt-signaling pathway as active in ALL [33]. This
is relevant, since Wnt-dependent cellular processes have
been shown to be critical for solid organ malignancies,
and as therapeutics are already in development for applica-
tion in solid neoplasms, most notably heaptocellular and
colon carcinomas [34,35], it is plausible that they would
have a role in chemotherapy for ALL as well.
Terms identiﬁed as relevant in AML include those of
immune and inﬂammatory response, cell adhesion and
metal ion binding processes. This perhaps gives extra
weights to a recently identiﬁed, yet not completely under-
stood, property of AML to be more susceptible to eradica-
tion by immune means than ALL [36]. In fact, the success
of hematopoietic stem cell transplantation for AML maybe
in a large part a result of graft vs. leukemia eﬀect, i.e.,
immune mediated [37].4.4.2. DLBCL vs. follicular lymphoma
Follicular and diﬀuse large B-cell lymphomas are two
common classes of lymphoma, malignancy that typically
I. Trajkovski et al. / Journal of Biomedical Informatics 41 (2008) 588–601 599involves lymph nodes, spleen, but can originate at other
sites, such as gastrointestinal tract, liver, throat, bone,
and brain. As expected, immune response pathways (for
follicular lymphoma), and DNA binding and replication
(key processes in transcriptional regulation of cell division
and proliferation in diﬀuse large B-cell lymphoma) domi-
nate the expression patterns [29,30].
4.4.3. Prostate cancer vs. normal tissue
Prostate cancer is the most common, non-dermatologic
male cancer. It represents 33% of cancers and is the third
leading cause of cancer deaths in men [28]. Thus, the
impact on public health is dramatic and any insights with
a potential of translation into viable preventive or thera-
peutic interventions are urgently needed. In this work,
the pathways active in gene transcription (upregulated in
any rapidly dividing cells, e.g., malignant cell) have been
identiﬁed: gene sets 1, 2 and 3 in prostate cancer (with
52, 45 and 51 genes, respectively in Table 3).
In addition, the investigations of normal cells of pros-
tate point, as expected in normal glandular tissue of pros-
tate, discovered groups of genes involved in cell adhesion,
Ras oncogene signal transduction, protein regulation
(phosphorylation by kinases), including surface membrane
receptors (gene sets 1–5 on normal prostate tissue in Table
3).
5. Conclusion and further work
This paper addresses the problem of ﬁnding enriched
functional groups of genes based on gene expression data.
The proposed SEGS method allows integration of GO and
KO gene annotations as well as the gene–gene interaction
data from ENTREZ into the construction of new interest-
ing relevant gene sets. The experimental results show that
the introduced method improves the statistical signiﬁcance
and the functional interpretation of gene expression data,
and we base our conclusion on the following facts:
• Enrichment scores of the newly constructed sets are bet-
ter then the enrichment scores of any single GO and KO
term.
• Newly constructed enriched gene sets can be described
by non-enriched GO and KO terms, which means that
we are extracting additional biological knowledge that
can not be found by single term enrichment analysis.
• This method is a generalization of traditional methods.
If we turn-oﬀ gene–gene interactions and intersections
of GO and KO terms, we get the classical single term
enrichment analysis.
This paper provides strongly suggesting evidence that
the proposed SEGS method indeed ﬁnds biologically rele-
vant terms not found by single term analysis (see the exam-
ples of terms commented by the medical expert in Section
4.4). The expert interpretation of the results of this study
shows that meaningful analysis of gene products actingjointly in biologically relevant ways is possible and that this
and future studies can provide support for transferring of
this new technology to clinic. An extensive study about
the relevance of the found terms (percentage of false posi-
tives) is planed in the future. Next, further work will also
aims at using discovered enriched gene sets as features
for classiﬁcation of microarray data. We believe that some
of these features will turn out to be statistically signiﬁcant
markers of speciﬁc diseases.
We believe that the impact of the proposed method will
be even greater given the expected increase in both the
quality and quantity of gene annotations and gene–gene
interaction data in the near future.
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Appendix A. SEGS procedures for generating gene sets
The pseudo code presented below is the part of the
SEGS algorithm. These procedures are generating all gene
sets that contain predeﬁned minimal number of genes (e.g.,
3) located at the top (e.g., ﬁrst 100) of the provided input
gene list.
01 topTerm = [‘molecular_function’,
‘biological_process’,
02 ‘cellular_component’, ‘kegg_pathway’]
03
04 function GENERATE-GENE-SETS(GeneList)
05 input: GeneList
06 output: gene_sets
07
08 gene_sets= []
09 BUILD-CLAUSE(0, [], GeneList[1:100], top-
Term[0], gene_sets)
10 return gene_sets
11
12 procedure BUILD-CLAUSE (depth, clause,
genes, term, gene_sets)
13 input: depth, clause, gene_set, term
14 output: gene_sets
15
16 new_genes=INTERSECTION (genes,
TERM_TO_GENES[term])
17 IF LENGTH(new_genes)>3 THEN # minimal
support ?
18 ADD(clause, term)
19 ADD(gene_sets, clause)
600 I. Trajkovski et al. / Journal of Biomedical Informatics 41 (2008) 588–60120 IF depth<4 THEN # add more terms
21 BUILD-CLAUSE(depth+1, clause,
new_genes,
22 topTerm[depth+1], gene_sets)
23 REMOVE(clause, term)
24 FOR EACH child IN CHILDREN(term)DO #
refine
25 BUILD-CLAUSE(depth, clause, new_
genes,
26 child, gene_sets)
The main function of the algorithm is the recursive func-
tion BUILD-CLAUSE. It tries to add a new term to the
given input clause (conjunction of terms). If the new clause
cover enough top genes (line 17) then it is added to the
resulting list of clauses that describe the new gene sets.
After the term is added the procedure recursively call itself
in order to add more terms in the clause (line 21) or to
reﬁne the added term (line 25). The provided code will gen-
erate all gene sets that have at least three genes in the top
100 genes of the GENELIST.
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